| # | Drug | Count |
|---|---|---|
| 0 | CLOZAPINE | 2283 |
| 1 | NIVOLUMAB | 1040 |
| 2 | OLANZAPINE | 808 |
| 3 | QUETIAPINE | 556 |
| 4 | CARBOPLATIN | 530 |
| 5 | IPILIMUMAB | 520 |
| 6 | PREDNISONE | 498 |
| 7 | ACETAMINOPHEN | 444 |
| 8 | ARIPIPRAZOLE | 427 |
| 9 | ACETAMINOPHEN 500MG | 369 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PENPULIMAB | 6 | 0.0612 |
| 1 | NIVOLUMAB AND RELATLIMAB-RMBW | 19 | 0.0369 |
| 2 | AMISULPRIDE | 217 | 0.0354 |
| 3 | CHLORPROMAZINE HYDROCHLORIDE | 27 | 0.0283 |
| 4 | PLATINUM | 13 | 0.0245 |
| 5 | DELANDISTROGENE MOXEPARVOVEC-ROKL | 9 | 0.0245 |
| 6 | CEMIPLIMAB-RWLC | 50 | 0.0240 |
| 7 | TREMELIMUMAB | 100 | 0.0226 |
| 8 | CLOZAPINE | 2283 | 0.0181 |
| 9 | BENZTROPINE | 117 | 0.0157 |
| # | Drug class | Count |
|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 2706 |
| 1 | Atypical Antipsychotic [EPC] | 2673 |
| 2 | Corticosteroid [EPC] | 1200 |
| 3 | Nonsteroidal Anti-inflammatory Drug [EPC] | 926 |
| 4 | Benzodiazepine [EPC] | 769 |
| 5 | Platinum-based Drug [EPC] | 751 |
| 6 | CTLA-4-directed Blocking Antibody [EPC] | 608 |
| 7 | Kinase Inhibitor [EPC] | 480 |
| 8 | Proton Pump Inhibitor [EPC] | 433 |
| 9 | Microtubule Inhibitor [EPC] | 419 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 29 | 0.0422 |
| 1 | Lymphocyte Activation Gene-3 Blocker [EPC] | 19 | 0.0369 |
| 2 | Dopamine-2 Receptor Antagonist [EPC] | 218 | 0.0280 |
| 3 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 2706 | 0.0274 |
| 4 | Human Immunoglobulin [EPC] | 1 | 0.0196 |
| 5 | Programmed Death Ligand-1 Blocker [EPC] | 317 | 0.0147 |
| 6 | CTLA-4-directed Blocking Antibody [EPC] | 608 | 0.0126 |
| 7 | Lymphocyte Growth Factor [EPC] | 15 | 0.0119 |
| 8 | CD38-directed Cytolytic Antibody [EPC] | 47 | 0.0080 |
| 9 | Typical Antipsychotic [EPC] | 201 | 0.0080 |